Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) insider Jeffrey Kunins sold 9,605 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the sale, the insider owned 97,761 shares in the company, valued at approximately $61,266,818.70. The trade was a 8.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Axon Enterprise Price Performance
Shares of AXON opened at $597.59 on Tuesday. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $794.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The business's 50 day moving average price is $546.20 and its two-hundred day moving average price is $478.02. The firm has a market cap of $48.55 billion, a PE ratio of 247.96, a price-to-earnings-growth ratio of 10.19 and a beta of 1.39.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.84 by $0.04. The company had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. Axon Enterprise's revenue for the quarter was up 35.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.12 EPS. On average, equities analysts anticipate that Axon Enterprise, Inc will post 2.04 EPS for the current year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on AXON shares. UBS Group increased their price objective on shares of Axon Enterprise from $440.00 to $600.00 and gave the stock a "neutral" rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 10th. Needham & Company LLC reiterated a "buy" rating on shares of Axon Enterprise in a report on Thursday, August 6th. Finally, Piper Sandler raised their price objective on Axon Enterprise from $724.00 to $732.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $730.92.
Read Our Latest Stock Report on AXON
Institutional Trading of Axon Enterprise
Several institutional investors and hedge funds have recently made changes to their positions in AXON. Carlson Financial Inc. boosted its holdings in Axon Enterprise by 2.7% during the second quarter. Carlson Financial Inc. now owns 16,039 shares of the biotechnology company's stock worth $8,992,000 after purchasing an additional 415 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Axon Enterprise by 55,955.7% during the 2nd quarter. California State Teachers Retirement System now owns 64,781,849 shares of the biotechnology company's stock worth $36,317,352,000 after buying an additional 64,666,282 shares in the last quarter. Washington Trust Advisors Inc. lifted its position in shares of Axon Enterprise by 1,300.0% during the 2nd quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company's stock worth $39,000 after buying an additional 65 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of Axon Enterprise in the 2nd quarter worth approximately $236,000. Finally, Nvest Financial LLC grew its holdings in shares of Axon Enterprise by 10.4% in the second quarter. Nvest Financial LLC now owns 777 shares of the biotechnology company's stock valued at $436,000 after acquiring an additional 73 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
